title: [The role of rivastigmine (exelon) in the treatment of consequences of cranial-brain trauma].
abstract: The use of rivastigmine in the rehabilitation of patients with cognitive disturbances after cranial-brain trauma (CBT) is reviewed. Replacement of cholinergic deficit exerts a positive effect on sanogenetic process in the brain, facilitate consolidation and learning of afferent information in the restoring brain. The authors emphasize that the administration of neuromediator preparations needs the level of organization of integrative brain activity which is sufficient for the formation of awakening reaction (opening of eyes - awakening from coma). It is suggested that neuromediator preparations, in particular cholinesterase inhibitor rivastigmine, should be used after the acutest CBT period, i.e. at least 2-3 weeks after CBT, when the main acute processes have been stabilized.
authors.forename: E A
authors.initials: EA
authors.lastname: Kondrat'eva
authors.forename: V N
authors.initials: VN
authors.lastname: Borovikova
authors.forename: S A
authors.initials: SA
authors.lastname: Kondrat'ev
authors.forename: N V
authors.initials: NV
authors.lastname: Driagina
authors.forename: V A
authors.initials: VA
authors.lastname: Voronenko
mesh_terms: D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003071:Cognition / Q000187:drug effects / Q000502:physiology*; D003072:Cognition Disorders / Q000209:etiology / Q000517:prevention & control* / Q000523:psychology; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D048448:Phenylcarbamates / Q000627:therapeutic use*; D000068836:Rivastigmine; D016896:Treatment Outcome
chemical_list: D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine